| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | GeneticVariation | disease | BEFREE | Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. | 31760835 | 2020 | ||||
|
0.090 | Biomarker | disease | BEFREE | In AML, CPX-351 offers a new induction chemotherapy for secondary AML that prolongs survival, and venetoclax and IDH inhibitors are efficacious and well tolerated. | 30848394 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | A recent phase 3 trial showed that outcome of older patients with secondary acute myeloid leukemia (AML) may be improved by a liposomal encapsulation of cytarabine and daunorubicin (CPX-351). | 31173485 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail. | 31203994 | 2019 | ||||
|
0.090 | GeneticVariation | disease | BEFREE | Patients and Methods In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. | 30024784 | 2018 | ||||
|
0.090 | Biomarker | disease | BEFREE | CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. | 29378418 | 2018 | ||||
|
0.090 | Biomarker | disease | BEFREE | Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. | 29928134 | 2018 | ||||
|
0.090 | Biomarker | disease | BEFREE | Further studies are required to prospectively compare FLAG to the newly FDA-approved CPX-351 in sAML. | 29908418 | 2018 | ||||
|
0.090 | Biomarker | disease | BEFREE | Specifically, synergistic combination of daunorubicin and cytarabine (i.e., CPX-351) was found to improve OS in sAML patients. | 28030373 | 2017 |